Nuvo Pharmaceuticals Inc.

TSX:MRV Stock Report

Market Cap: CA$15.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Nuvo Pharmaceuticals Valuation

Is MRV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MRV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MRV (CA$1.35) is trading below our estimate of fair value (CA$7.14)

Significantly Below Fair Value: MRV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MRV?

Key metric: As MRV is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for MRV. This is calculated by dividing MRV's market cap by their current earnings.
What is MRV's PE Ratio?
PE Ratio1x
EarningsCA$15.17m
Market CapCA$15.37m

Price to Earnings Ratio vs Peers

How does MRV's PE Ratio compare to its peers?

The above table shows the PE ratio for MRV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.7x
ATL Atlas Global Brands
0.9xn/aCA$23.8m
HASH Simply Solventless Concentrates
63xn/aCA$53.2m
MDP Medexus Pharmaceuticals
16.2x55.2%CA$52.3m
VEXT Vext Science
n/a111.1%CA$48.2m
MRV Nuvo Pharmaceuticals
1xn/aCA$15.4m

Price-To-Earnings vs Peers: MRV is good value based on its Price-To-Earnings Ratio (1x) compared to the peer average (17x).

Price to Earnings Ratio vs Industry

How does MRV's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?

14 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.18.3x54.4%
MRV Nuvo Pharmaceuticals
 1xn/aUS$11.21m
MRV 1.0xIndustry Avg. 18.3xNo. of Companies14PE01224364860+
14 CompaniesEstimated GrowthMarket Cap
Industry Avg.18.3x54.4%
MRV Nuvo Pharmaceuticals
 1xn/aUS$11.21m
No more companies

Price-To-Earnings vs Industry: MRV is good value based on its Price-To-Earnings Ratio (1x) compared to the North American Pharmaceuticals industry average (14.4x)

Price to Earnings Ratio vs Fair Ratio

What is MRV's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MRV PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio1x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MRV's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Medexus Pharmaceuticals

CA$52.3m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.12

7D

-2.3%

1Y

22.5%

Verano Holdings

CA$845.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.37

7D

-12.5%

1Y

-60.7%

Cresco Labs

CA$868.4m

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States.

CL

CA$1.97

7D

13.9%

1Y

-19.6%